- Home
- MVSTW vs SBFM Comparison
MVSTW vs SBFM Comparison
Compare MVSTW & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVSTW
- SBFM
- Stock Information
- Founded
- MVSTW 2006
- SBFM 2006
- Country
- MVSTW United States
- SBFM United States
- Employees
- MVSTW 1921
- SBFM N/A
- Industry
- MVSTW Industrial Machinery/Components
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- MVSTW Miscellaneous
- SBFM Health Care
- Exchange
- MVSTW Nasdaq
- SBFM Nasdaq
- Market Cap
- MVSTW N/A
- SBFM 7.7M
- IPO Year
- MVSTW N/A
- SBFM N/A
- Fundamental
- Price
- MVSTW N/A
- SBFM $1.54
- Analyst Decision
- MVSTW
- SBFM Strong Buy
- Analyst Count
- MVSTW 0
- SBFM 1
- Target Price
- MVSTW N/A
- SBFM $15.00
- AVG Volume (30 Days)
- MVSTW 126.0K
- SBFM 183.8K
- Earning Date
- MVSTW 03-14-2025
- SBFM 08-15-2025
- Dividend Yield
- MVSTW N/A
- SBFM N/A
- EPS Growth
- MVSTW N/A
- SBFM N/A
- EPS
- MVSTW N/A
- SBFM N/A
- Revenue
- MVSTW $370,989,000.00
- SBFM $36,234,578.00
- Revenue This Year
- MVSTW N/A
- SBFM $192.48
- Revenue Next Year
- MVSTW N/A
- SBFM N/A
- P/E Ratio
- MVSTW N/A
- SBFM N/A
- Revenue Growth
- MVSTW 39.03
- SBFM 35.51
- 52 Week Low
- MVSTW $0.35
- SBFM $1.17
- 52 Week High
- MVSTW $0.44
- SBFM $7.60
- Technical
- Relative Strength Index (RSI)
- MVSTW N/A
- SBFM 53.29
- Support Level
- MVSTW N/A
- SBFM $1.42
- Resistance Level
- MVSTW N/A
- SBFM $1.75
- Average True Range (ATR)
- MVSTW 0.00
- SBFM 0.12
- MACD
- MVSTW 0.00
- SBFM 0.01
- Stochastic Oscillator
- MVSTW 0.00
- SBFM 44.44
About MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.